Epigenetics SolutionS

---

Corrective gene therapy which is already being used in the treatment of prostate cancer involves replacement or inactivation of a defective gene, such as a mutated tumor suppressor or a dominant oncogene found to play role in the pathogenesis

The tumor suppressor gene therapies that have been investigated in prostate cancer include p53, RB (retinobla-toma) and p21. The introduction of normal (wild-type) p53 into prostate cancer in vitro and in vivo suppresses malignant phenotype and growth.

Men with a type of advanced prostate cancer who received a PSMA-targetting drug lived longer than those who received standard thereapies and in July 2023 the FDA granted a fast track designation to the novel drug ARX517 for the treatment of patients with metastatic castration-resistant prostate cancer